CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity

Acta Pharmacologica Sinica

Volumn 31, Issue 2, 2010, Pages 165-174

  Qi, Min You ^a   Feng, Yu ^a   Dai, De Zai ^a   Li, Na ^a   Cheng, Yu Si ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Berberine; Calcium leakage; Endothelin; FKBP12.6; Heart failure; Oxidative stress; Phospholamban; SERCA2a; Sprague Dawley rats

Indexed keywords

AMINOGUANIDINE; ANTIOXIDANT; ASCORBIC ACID; BERBERINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CALSTABIN 2; CARDIAC AGENT; CARRIER PROTEIN; CPU 86017; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIN CONVERTING ENZYME; ISOPRENALINE; MESSENGER RNA; PHOSPHOLAMBAN; PREPROENDOTHELIN 1; PROPRANOLOL; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CELL ISOLATION; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DIASTOLIC BLOOD PRESSURE; DOWN REGULATION; FLUORESCENCE ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ANIMALS; ANTIOXIDANTS; BASE SEQUENCE; BERBERINE; CALCIUM; CALCIUM-BINDING PROTEINS; DNA PRIMERS; DOWN-REGULATION; HEART FAILURE; IMMUNOHISTOCHEMISTRY; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 76949094803     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.180     Document Type: Article

References (41)

1. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci USA 2006; 103: 511-8.
2. Lehnart SE, Wehrens XH, Kushnir A, Marks AR. Cardiac ryanodine receptor function and regulation in heart disease. Ann NY Acad Sci 2004; 1015: 144-59.
3. Lehnart SE. Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr Opin Pharmacol 2007; 7: 225-32.
4. Reiken S, Gaburjakova M, Guatimosim S, Gomez AM, D'Armiento J, Burkhoff D, et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem 2003; 278: 444-53.
5. Ellison GM, Torella D, Karakikes I, Purushothaman S, Curcio A, Gasparri C, et al. Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J Biol Chem 2007; 282: 11397-409.
6. Wang HL, Dai DZ, Gao E, Zhang YP, Lu F. Dispersion of ventricular mRNA of RyR2 and SERCA2 associated with arrhythmogenesis in rats. Acta Pharmacol Sin 2004; 25: 738-43.
7. Feng Y, Tang XY, Dai DZ, Dai Y. Reversal of isoproterenol induced downregulation of phospholamban and FKBP12.6 is mediated by antagonism of endothelin receptors of CPU0213. Acta Pharmacol Sin. 2007; 28: 1746-54.
8. Li N, Jia N, Dai DZ, Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKC epsilon. Eur J Pharmacol 2008; 591: 211-8.
9. Cheng YS, Dai DZ, Dai Y. Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213. Acta Pharmacol Sin 2009; 30: 1099-1106
10. Qi MY, Xia HJ, Dai DZ, Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to upregulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006; 47: 729-35.
11. Phrommintikul A, Chattipakorn N. Roles of cardiac ryanodine receptor in heart failure and sudden cardiac death. Int J Cardiol 2006; 112: 142-52.
12. Marks AR. Novel therapy for heart failure and exercise-induced ventricular tachycardia based on 'fixing' the leak in ryanodine receptors. Novartis Found Symp 2006; 274: 132-47.
13. Gyorke S, Terentyev D. Modulation of ryanodine receptor by luminal calcium and accessory proteins in health and cardiac disease. Cardiovasc Res 2008; 77: 245-55.
14. Shattock MJ. Phospholemman: its role in normal cardiac physiology and potential as a druggable target in disease. Curr Opin Pharmacol 2009; 9: 160-6.
15. Gao MH, Tang T, Guo T, Miyanohara A, Yajima T, Pestonjamasp K, et al. Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes. J Biol Chem 2008; 283: 33527-35.
16. Dai DZ. CPU86017: a novel Class III antiarrhythmic agent with multiple actions at ion channels. Cardiovasc Drug Rev 2006; 24: 101-15.
17. Zhang TT, Cui B, Dai DZ, Tang XY. Pharmacological efficacy of CPU 86017 on hypoxic pulmonary hypertension in rats: mediated by direct inhibition of calcium channels and antioxidant action, but indirect effects on the ET-1 pathway. J Cardiovasc Pharmacol 2005; 46: 727-34.
18. Zhang TT, Cui B, Dai DZ, Su W. CPU 86017, p-chlorobenzyltetrahyd roberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway. Acta Pharmacol Sin 2005; 26: 1309-16.
19. Sumitomo N, Harada K, Nagashima M, Yasuda T, Nakamura Y, Aragaki Y, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66-70.
20. Kontula K, Laitinen PJ, Lehtonen A, Toivonen L, Viitasalo M, Swan H. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights. Cardiovasc Res 2005; 67: 379-87.
21. Nakamura R, Egashira K, Machida Y, Hayashidani S, Takeya M, Utsumi H, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation 2002; 106: 362-7.
22. Brigadeau F, Gelé P, Marquié C, Soudan B, Lacroix D. Ventricular arrhythmias following exposure of failing hearts to oxidative stress in vitro. J Cardiovasc Electrophysiol 2005; 16: 629-36.
23. Kao JP, Harootunian AT, Tsien RY. Photochemically generated cytosolic calcium pulses and their detection by fluo-3. J Biol Chem 1989; 264: 8179-84.
24. Huang ZJ, Dai DZ, Li N, Na T, Ji M, Dai Y. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits. Clin Exp Pharmacol Physiol 2007; 34: 310-7.
25. Ishibashi Y, Takahashi N, Tokumaru A, Karino K, Sugamori T, Sakane T, et al. Activation of inducible NOS in peripheral vessels and outcomes in heart failure patients. J Card Fail 2008; 14: 724-31.
26. Han JM, Chang BJ, Li TZ, Choe NH, Quan FS, Jang BJ, et al. Protective effects of ascorbic acid against lead-induced apoptotic neurodegeneration in the developing rat hippocampus in vivo. Brain Res 2007; 1185: 68-74.
27. Minamisawa S, Sato Y, Cho MC. Calcium cycling proteins in heart failure, cardiomyopathy and arrhythmias. Exp Mol Med 2004; 36: 193-203.
28. Lokuta AJ, Maertz NA, Meethal SV, Potter KT, Kamp TJ, Valdivia HH, et al. Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure. Circulation 2005; 111: 988-95.
29. Du XJ, Cox HS, Dart AM, Esler MD. Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure. Cardiovasc Res 1999; 43: 919-29.
30. Elhendy A, Sozzi FB, van Domburg RT, Bax JJ, Geleijnse ML, Roelandt JR. Relation among exercise-induced ventricular arrhythmias, myocardial ischemia, and viability late after acute myocardial infarction. Am J Cardiol 2000; 86: 723-9.
31. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106: 69-74.
32. Currie S. Cardiac ryanodine receptor phosphorylation by CaM Kinase II: keeping the balance right. Front Biosci 2009; 14: 5134-56.
33. Chakraborti S, Das S, Kar P, Ghosh B, Samanta K, Kolley S, et al. Calcium signaling phenomena in heart diseases: a perspective. Mol Cell Biochem 2007; 298: 1-40.
34. Vittone L, Mundina-Weilenmann C, Mattiazzi A. Phospholamban phosphorylation by CaMKII under pathophysiological conditions. Front Biosci 2008; 13: 5988-6005.
35. Kaye DM, Preovolos A, Marshall T, Byrne M, Hoshijima M, Hajjar R, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 2007; 50: 253-60.
36. Hao JM, Dai DZ, Yu F. The exaggerated oxidative stress developed in cardiomyopathy by over-doses of thyroxin and these were reversed partly by CPU86017, a derivative of tetra-hydro-berberine. J Advan Pharm Sci 2005; 29: 417-21.
37. Na T, Huang ZJ, Dai DZ, Zhang Y, Dai Y. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017. Acta Pharmacol Sin 2007; 28: 773-82.
38. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 1149-54.
39. Yano M, Kobayashi S, Kohno M, Doi M, Tokuhisa T, Okuda S, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation 2003; 107: 477-84.
40. Yamamoto T, Yano M, Xu X, Uchinoumi H, Tateishi H, Mochizuki M, et al. Identification of target domains of the cardiac ryanodine receptor to correct channel disorder in failing hearts. Circulation 2008; 117: 762-72.
41. Hassoun SM, Marechal X, Montaigne D, Bouazza Y, Decoster B, Lancel S, et al. Prevention of endotoxin-induced sarcoplasmic reticulum calcium leak improves mitochondrial and myocardial dysfunction. Crit Care Med 2008; 36: 2590-6.